Charles River Laboratories International, Inc. (CRL) Upgraded to Overweight at JP Morgan

Market Context

Charles River Laboratories International, Inc. operates in the Healthcare sector. The stock currently trades at $260.21 with a market capitalization of $9.6B. The stock has gained 60.9% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. JP Morgan's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Charles River Laboratories International, Inc.

Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 06, 2026	JP Morgan	Overweight	N/A
Jul 20, 2026	CLSA	Hold	N/A
Jul 13, 2026	Mizuho	Neutral	N/A
Jul 09, 2026	Morgan Stanley	Overweight	N/A
Jun 17, 2026	Morgan Stanley	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View CRL Stock Page